Please login to the form below

Not currently logged in
Email:
Password:

GW Pharma

This page shows the latest GW Pharma news and features for those working in and with pharma, biotech and healthcare.

Blackwood returns as new life sciences minister

Blackwood returns as new life sciences minister

companies including GW Pharma. ... Roche, Celgene, IQVIA and Oxford Biomedica. Her role also includes looking at ways in which the sector can make the most of Brexit - although the UK's pharma and biotech sector

Latest news

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    drugs, driven on by new pharma and biotech science, and the FDA's determination to accelerate its review times. ... in the body where the tumour originated (after Merck &Co’s Keytruda), and GW Pharma’s epilepsy therapy Epidiolex (cannabidiol) which

  • UK life sciences gets some Brexit relief with £1.3bn sector deal UK life sciences gets some Brexit relief with £1.3bn sector deal

    Another £200m is coming from other pharma companies. That includes £46m package from IQVIA that will go towards the creation of the organisation’s fourth ‘Prime Site’ for clinical research – a ... CRUK is also pitching in with a £14m

  • Medical cannabis now available on prescription, for some Medical cannabis now available on prescription, for some

    Meanwhile, GW Pharma – which has been cultivating medicinal cannabis in the UK for more than 20 years – just recently got approval and favourable scheduling for its cannabis-based epilepsy therapy Epidiolex

  • US approval for first ever cannabis-based medicine US approval for first ever cannabis-based medicine

    Once this recategorisation is completed within the next 90 days, GW Pharma will launch Epidiolex in the US. ... GW Pharma has already filed with the FDA for a second indication, in Tuberous Sclerosis Complex, with a decision expected in Q1 2019.

  • GW ascendant as epilepsy drug clears phase III trial GW ascendant as epilepsy drug clears phase III trial

    Cannabis-based drug specialist GW Pharma saw its shares soar yesterday after reporting impressive phase III results for its epilepsy drug candidate. ... GW has been scaling up its commercial organisation and production capacity in anticipation of

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2014 Pharma deals during January 2014

    Another option, open to some European companies, is to raise cash in the US, for example, in early January GW Pharma raised $87.9m on NASDAQ. . ... See a table listing all the major pharma mergers, acquisitions and collaborations agreed during January

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    I look forward to contributing to GW’s drug discovery efforts and to advancing the next generation of pipeline candidates.”. ... Justin Gover, GW’s chief executive officer, said: “I am delighted to welcome Volker and Ben to GW in these important R

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    Gover said: “These important leadership appointments reflect GW’s continuing evolution into a transatlantic commercial-stage biopharmaceutical company. ... In his new role he will be tasked with ensuring GW’s UK operations achieve their strategic

  • GW Pharma appoints Julian Gangolli as North American president GW Pharma appoints Julian Gangolli as North American president

    Appointment coincides with GW Pharma’s US launch. Biopharma company GW Pharma has named Julian Gangolli as its president for North America. ... GW Pharma is also relocating its CEO, Justin Glover, to the US to support its imminent launch in the States.

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    Appointed VP clinical research at company specialising in cannabinoids. Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma. ... This is an exciting time to be joining GW, with a number of important products currently under

More from appointments
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics